NCT07116694View on ClinicalTrials.gov

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Bipolar I DisorderBipolar II DisorderSchizophreniaSchizoaffective DisorderSchizophreniform DisordersPsychomotor Agitation
Interventions
DRUG

BXCL501 Sublingual Film

Single dose BXCL501 120 mcg

Trial Locations (5)

63125

BioXcel Clinical Research Site 101, St Louis

89119

BioXcel Clinical Research Site 106, Las Vegas

91710

BioXcel Clinical Research Site 103, Chino

92056

BioXcel Clinical Research Site 105, Oceanside

92868

BioXcel Clinical Research Site 102, Orange

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

BioXcel Therapeutics Inc

INDUSTRY